News >

FDA Approves FoundationOne CDx, CMS Agrees to Cover

Jason Harris
Published: Thursday, Nov 30, 2017

The FDA has approved the FoundationOne CDx (F1CDx) cancer biomarker assay concurrently with a decision from the Centers for Medicare & Medicaid Services (CMS) to provide insurance coverage for the next-generation sequencing (NGS)-based in vitro diagnostic (IVD) test.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x